Combining in silico modeling, in vitro T cell activation properties, and in vivo anti-leukemia activity has identified promising VIP-R antagonist candidates for further development as novel immunotherapies for patients with AML having relapsed disease. Here, VIPR1 is linked to acute myeloid leukemia.